Mechanisms of action of infliximab in inflammatory bowel disease: an anti-inflammatory multitasker.
Journal: Digestive And Liver Disease : Official Journal Of The Italian Society Of Gastroenterology And The Italian Association For The Study Of The Liver
Published:
Abstract
The pro-inflammatory cytokine tumor necrosis factor-alpha (TNF-alpha) plays a central role in mucosal inflammation and is a key mediator in the inflammatory cascade in both Crohn's disease (CD) and ulcerative colitis (UC). Infliximab, a monoclonal antibody against TNF-alpha has been proved highly effective in the clinical management of both forms of IBD. Aim of this paper is to review the mechanisms of action of infliximab in IBD.
Authors
S Danese
Relevant Conditions